IP Library Granted Patent US 9,751,838
Granted Patent B2
US 9,751,838 · App. 14/432,768 · Granted Sep 5, 2017

Tetrahydroquinoline derivatives and their use as Epac inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,751,838
App. No.
14/432,768
Granted
Sep 5, 2017
Kind
B2
Abstract

The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.

Claims (24)

1. A method of treatment of a disease, disorder, or condition, or one or more symptoms thereof wherein the Epac protein is involved, said method comprising the administration of a pharmaceutically acceptable amount of a compound of formula (I) to a patient in need thereof:

wherein:

R9 is

and

is the attachment to the nitrogen atom of the tetrahydroquinoline;

R1, R2, R3, R4 and R8 are independently chosen from the group consisting of:

H and (C 1 -C 5 );

R5 is an halogen atom;

R6 and R7 are independently chosen from the group consisting of H and halogen atoms;

or its pharmaceutically acceptable salts, hydrates or hydrated salts, racemates, diastereomers or enantiomers,

wherein said compound of formula (I) is a selective inhibitor of EPAC1, and

wherein the disease, disorder, or condition is selected from cardiac diseases, wherein said cardiac diseases are selected from the group consisting of cardiac hypertrophy, cardiac arrhythmias, valvulopathies, diastolic dysfunction, chronic heart failure, ischemic heart failure, myocarditis, hypertrophic and dilated cardiomyopathies.

2. The method according to claim 1 , wherein in the compound of formula (I) R1 is H.

3. The method according to claim 1 , wherein in the compound of formula (I) R2 is H or a (C 1 -C 5 )alkyl.

4. The method according to claim 1 , wherein in the compound of formula (I) R2 is H or a methyl group.

5. The method according to claim 1 , wherein in the compound of formula (I) R5 and/or R6 is selected from the group consisting of F, Cl, Br and I.

6. The method according to claim 1 , wherein in the compound of formula (I) R6 is H or F.

7. The method according to claim 1 , wherein in the compound of formula (I) R7 is selected from the group consisting of H, F, Cl, Br and I.

8. The method according to claim 1 , wherein in the compound of formula (I) R7 is H or Br.

9. The method according to claim 1 , wherein in the compound of formula (I) R1 is H and R5 is Br.

10. The method according to claim 1 , wherein in the compound of formula (I) at least two of R5, R6 and R7 are halogen.

11. The method according to claim 1 , wherein the compound of formula (I) has one of the following formulae:

12. A compound having the following formula:

13. The method according to claim 1 , wherein R1, R2, R3, R4 and R8 are independently chosen from the group consisting of H and (C 1 -C 4 )alkyl.

Assignments (2)
MERGER Recorded Aug 22, 2022
From: UNIVERSITE DE PARIS 11 - PARIS SUD (ALSO NAMED UNIVERSITÉ PARIS-SUD)
To: UNIVERSITE PARIS-SACLAY
Reel/Frame 060856/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2015
From: LEZOUALC'H, FRANK; FISCHMEISTER, RODOLPHE; BISSERIER, MALIK; BOUYSSOU, PASCAL; BLONDEAU, JEAN-PAUL; COURILLEAU, DELPHINE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE PAUL SABATIER TOULOUSE III; UNIVERSITE PARIS-SUD; UNIVERSITE D'ORLEANS
Reel/Frame 035741/0451 →